Compare AU

Compare CURE vs. IISV

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Intell Invest Select Value Shr Fund (Managed Fund) (IISV). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

IISV

Popularity

Low

Low

Pearlers invested

83

10

Median incremental investment

$619.50

$596.46

Median investment frequency

Monthly

Monthly

Median total investment

$1,467.76

$5,415.93

Average age group

> 35

26 - 35


Key Summary

CURE

IISV

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

IISV.AX was created on 2023-03-31 by Intelligent Investor . The fund's investment portfolio concentrates primarily on total market equity. The portfolio aims to outperform the S&P/ASX 200 Accumulation Index p.a. over five year rolling periods with minimal turnover to allow returns to compound in a favourable tax environment

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.96 %)

Gilead Sciences Inc (2.80 %)

RPMGlobal Holdings Ltd (7.77 %)

Fairfax Financial Holdings Ltd Shs Subord.Vtg (6.95 %)

KKR & Co Inc Ordinary Shares (5.57 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Financials (50.65 %)

Consumer Discretionary (15.93 %)

Information Technology (14.85 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.97 %


Key Summary

CURE

IISV

Issuer

Global X

Intelligent Investor

Tracking index

S&P Biotechnology Select Industry

S&P/ASX 200 Accumulation Index - AUD - Benchmark TR Net

Asset class

ETF

ETF

Management fee

0.45 %

0.97 %

Price

$52.35

$3.53

Size

$36.301 million

N/A

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

0.07 %

Market

ASX

ASX

First listed date

12/11/2018

30/03/2023

Purchase fee

$6.50

$6.50


Community Stats

CURE

IISV

Popularity

Low

Low

Pearlers invested

83

10

Median incremental investment

$619.50

$596.46

Median investment frequency

Monthly

Monthly

Median total investment

$1,467.76

$5,415.93

Average age group

> 35

26 - 35


Pros and Cons

CURE

IISV

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

IISV

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home